Who are Symbicort Turbohaler's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Salmeterol 50 mcg via DISKUS, Seretide Evohaler, long-acting beta2-agonist, Symbicort TBH - Turbuhaler, Salmeterol/Fluticasone propionate combination product, Symbicort Turbuhaler.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/symbicort-turbohaler.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Symbicort Turbohaler — Competitive Intelligence Brief

Symbicort Turbohaler (Symbicort Turbohaler) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Corticosteroid and long-acting beta2-adrenergic receptor agonist combination. Area: Respiratory.

phase 3 Corticosteroid and long-acting beta2-adrenergic receptor agonist combination Beta2-adrenergic receptor Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Symbicort Turbohaler (Symbicort Turbohaler) — Pearl Therapeutics, Inc.. Symbicort Turbohaler is a combination of budesonide and formoterol, a corticosteroid and a long-acting beta2-adrenergic receptor agonist, respectively, used to control symptoms of asthma and chronic obstructive pulmonary disease (COPD).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Symbicort Turbohaler TARGET	Symbicort Turbohaler	Pearl Therapeutics, Inc.	phase 3	Corticosteroid and long-acting beta2-adrenergic receptor agonist combination	Beta2-adrenergic receptor
Salmeterol 50 mcg via DISKUS	Salmeterol 50 mcg via DISKUS	GlaxoSmithKline	marketed	Long-acting beta2-adrenergic agonist (LABA)	Beta2-adrenergic receptors
Seretide Evohaler	Seretide Evohaler	FLUIDDA nv	phase 3	Corticosteroid and long-acting beta2-adrenergic receptor agonist combination	Beta2-adrenergic receptor
long-acting beta2-agonist	long-acting beta2-agonist	National Heart, Lung, and Blood Institute (NHLBI)	phase 3	Long-acting beta2-agonist (LABA)	Beta2-adrenergic receptor
Symbicort TBH - Turbuhaler	Symbicort TBH - Turbuhaler	AstraZeneca	phase 3	Corticosteroid and long-acting beta2-adrenergic receptor agonist combination	Beta2-adrenergic receptor
Salmeterol/Fluticasone propionate combination product	Salmeterol/Fluticasone propionate combination product	GlaxoSmithKline	phase 3	Long-acting beta2-adrenergic receptor agonist/inhaled corticosteroid combination	Beta2-adrenergic receptor
Symbicort Turbuhaler	Symbicort Turbuhaler	Orion Corporation, Orion Pharma	phase 3	Inhaled corticosteroid and long-acting beta2-adrenergic receptor agonist combination	Beta2-adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Corticosteroid and long-acting beta2-adrenergic receptor agonist combination class)

AstraZeneca · 1 drug in this class
Chiesi Farmaceutici S.p.A. · 1 drug in this class
FLUIDDA nv · 1 drug in this class
Pearl Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Symbicort Turbohaler — Competitive Intelligence Brief. https://druglandscape.com/ci/symbicort-turbohaler. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab